Why the study?
GnRH agonists used in ADT for prostate cancer are associated with increased cardiovascular disease risk, and challenges exist in routine cardiovascular risk assessment and multidisciplinary care.
Multidisciplinary consensus recommends routine cardiovascular risk assessment and preferential use of GnRH antagonists in prostate cancer patients with high CVD risk undergoing ADT.
Answers are grounded in this paper and cite their sources.
Supports integrating CV risk assessment into ADT care; extends prior evidence with multidisciplinary consensus on GnRH antagonists.
PURPOSE: Androgen deprivation therapy (ADT) is the mainstay approach for prostate cancer (PCa) management. However, the most commonly used ADT modality, gonadotropin-releasing hormone (GnRH) agonists, has been associated with an increased risk of cardiovascular disease (CVD). METHODS: The PCa Cardiovascular (PCCV) Expert Network, consisting of multinational urologists, cardiologists and oncologists with expertise in managing PCa, convened to discuss challenges to routine cardiovascular risk assessment in PCa management, as well as how to mitigate such risks in the current treatment landscape. RESULTS: The experts identified several barriers, including lack of awareness, time constraints, challenges in implementing risk assessment tools and difficulties in establishing multidisciplinary teams that include cardiologists. The experts subsequently provided practical recommendations to improve cardio-oncology care for patients with PCa receiving ADT, such as simplifying cardiovascular risk assessment, individualising treatment based on CVD risk categories, establishing multidisciplinary teams and referral networks and fostering active patient engagement. A streamlined cardiovascular risk-stratification tool and a referral/management guide were developed for seamless integration into urologists' practices and presented herein. The PCCV Expert Network agreed that currently available evidence indicates that GnRH antagonists are associated with a lower risk of CVD than that of GnRH agonists and that GnRH antagonists are preferred for patients with PCa and a high CVD risk. CONCLUSION: In summary, this article provides insights and guidance to improve management for patients with PCa undergoing ADT.
No takes yet. Share an insight, caveat, or question.
Merseburger et al. (2024) conducted a review in Prostate cancer. Cardiovascular risk assessment and multidisciplinary care was evaluated. The expert network recommends routine cardiovascular risk assessment using a simplified checklist, multidisciplinary care, and prioritizing GnRH antagonists for prostate cancer patients with high cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: